title: Remission as the treatment goal--the FIN-RACo trial.
abstract: The Finnish Rheumatoid Arthritis Combination Therapy (FIN-RACo) trial is the first rheumatoid arthritis (RA) clinical trial in which remission served as the primary outcome measure. This chapter reviews the philosophical background, study design, and results of the FIN-RACo trial. The study showed that a third of patients with active early RA may achieve remission with a combination of methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and prednisolone.
authors.affiliation: Jyväskylä Central Hospital, Jyväskylä, Finland. tuulikki.sokka@ksshp.fi
authors.forename: T
authors.initials: T
authors.lastname: Sokka
authors.forename: H
authors.initials: H
authors.lastname: Mäkinen
authors.forename: K
authors.initials: K
authors.lastname: Puolakka
authors.forename: T
authors.initials: T
authors.lastname: Möttönen
authors.forename: P
authors.initials: P
authors.lastname: Hannonen
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D023381:Endpoint Determination; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D012074:Remission Induction; D012107:Research Design; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D012460:Sulfasalazine; D006886:Hydroxychloroquine; D011239:Prednisolone; D008727:Methotrexate